Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 8/20 | 0.44 |
| ▸ | CNR1 | P21554 | 7/20 | 0.44 |
| ▸ | HRH2 | P25021 | 3/20 | 0.41 |
| ▸ | HRH1 | P35367 | 3/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838460 | 0.97 | MAPT (0.50) | MAPTSMN1; SMN2CNR2CNR1HRH2 | |
| SCHEMBL16746639 | 0.95 | MAPT (0.48) | MAPTSMN1; SMN2CNR2CNR1HRH2 | |
| SCHEMBL4570247 | 0.95 | MAPT (0.48) | MAPTSMN1; SMN2CNR2CNR1HRH2 | |
| SCHEMBL13427328 | 0.94 | MAPT (0.47) | MAPTSMN1; SMN2CNR2CNR1HRH2 | |
| SCHEMBL13182760 | 0.94 | MAPT (0.47) | MAPTSMN1; SMN2CNR2CNR1HRH2 | |
| SCHEMBL838132 | 0.92 | MAPT (0.46) | MAPTSMN1; SMN2CNR2CNR1HRH2 | |
| SCHEMBL13135373 | 0.92 | MAPT (0.46) | MAPTSMN1; SMN2CNR2CNR1HRH2 | |
| SCHEMBL13583857 | 0.91 | MAPT (0.47) | MAPTSMN1; SMN2CNR2CNR1HRH2 | |
| SCHEMBL13584035 | 0.91 | MAPT (0.47) | MAPTSMN1; SMN2CNR2CNR1HRH2 | |
| SCHEMBL14369604 | 0.90 | MAPT (0.44) | MAPTSMN1; SMN2CNR2CNR1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150145920-A1 | METHOD OF JETTING INK | XEROX CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
| US-9022546-B1 | Method of jetting ink | XEROX CORPORATION (US) | 2015-05-05 | — | — | US | disclosed |
| US-8916084-B2 | Ultra-violet curable gellant inks for three-dimensional printing and digital fabrication applications | XEROX CORPORATION (US) | 2014-12-23 | — | — | US | disclosed |
| US-8791202-B2 | Phase change ink compositions | XEROX CORPORATION (US) | 2014-07-29 | — | — | US | disclosed |
| US-8758865-B2 | Ultra-violet curable gellant inks for tactile and regular print applications for signature and document authentication | XEROX CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120123014-A1 | OVERPRINT VARNISH FORMULATIONS | XEROX CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-8142557-B2 | Radiation curable ink containing gellant and radiation curable wax | XEROX CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110316926-A1 | Organic Phase Change Carriers Containing Nanoparticles, Phase Change Inks Including Same and Methods for Making Same | XEROX CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| US-7905948-B2 | Phase change ink compositions | XEROX CORPORATION (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100116424-A1 | ORGANIC PHASE CHANGE CARRIERS CONTAINING NANOPARTICLES, PHASE CHANGE INKS INCLUDING SAME AND METHODS FOR MAKING SAME | XEROX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7625956-B2 | Phase change inks containing photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| US-7279587-B2 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070120910-A1 | Phase change inks containing photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | NR2E3, NR4A1, NR4A3 | MAPT 2052/4885SMN1; SMN2 4426/4885CNR2 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.